Navigation Links
Carmel Pharma Introduces PhaSeal Secondary Set (C60)

New Component Streamlines Safe Spiking, Priming and IV Bag Infusion with Hazardous Drugs

Columbus, OH (Vocus) October 31, 2009 -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, now offers the Secondary Set (C60) for safe, streamlined preparation and administration of IV bag infusions.

For safety and ease of use, the non-vented Secondary Set offers the following features:

  • Drip chamber (20 drops/mL)
  • Flow stop to facilitate priming of the Secondary Set from the bag prior to adding the drug
  • Universal spike with built-in PhaSeal Connector for safe, leakproof transfer of the drug to the IV bag
  • DEHP-free PVC tubing (40 in.)

For more information or to order, call 866-487-9250 or visit

PhaSeal is more than a system for the safe handling of hazardous drugs. It's the only clinically proven closed-system drug transfer device (CSTD) available today and is validated by more than 10 independent, peer-reviewed, published clinical studies. Distinguished by prominent thought leaders as the "Gold Standard" in safe handling, PhaSeal's airtight Expansion Chamber and leakproof Double Membrane connections prevent exposure to hazardous drugs, including aerosols and vapors, and make it the only system that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definition of a true CSTD. Its streamlined design and universally-compatible components make the system easy to use from preparation and administration to waste disposal.

The PhaSeal System is manufactured by Carmel Pharma AB in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the United States since 1998 and implemented in more than 1000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children's in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; SwedishAmerican Hospital in Rockford, IL; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit or email To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today's clinical thought leaders, please visit or contact Emily Frydendal at 614-318-2635 or emily.frydendal (at) carmelpharma (dot) com.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Carmel Pharma Introduces PhaSeal Secondary Set (C60)
2. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
3. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
4. China Pharma Holdings, Inc. to Report Third Quarter 2009 Financial Results on November 12, 2009
5. Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse
6. WuXi PharmaTech Schedules Third-Quarter 2009 Earnings Release
7. 5 Steps to Pharmaceutical Marketing Happiness
8. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
9. Vestara Awarded MedAssets Supplier Contract For Automated Pharmaceutical Waste Management Solution
10. CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
Related Image:
Carmel Pharma Introduces PhaSeal Secondary Set (C60) 
(Date:10/13/2017)... ... 13, 2017 , ... ProVest Insurance Group, a family managed ... Raleigh regions, is organizing an extended charity drive to benefit the family of ... , After struggling since birth with several health challenges, T.J. was later diagnosed ...
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: